RVVTF

• 

  Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

  10:34 AM | March 1, 2017

  TORONTO, ONTARIO– RVVTF, (Marketwired – Mar 1, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced the initiation of the research discovery program of cannabinoid-based therapeutics targeting liver diseases. The preclinical studies, including in vitro and in vitro pharmacology, will be conducted by PhytoSciences Consulting LLC, a contract research organization in Louisville, Kentucky. This novel investigation will

  Read more

• HEMP – Hemp, Inc. Shareholders to Receive Shares in New Fully Reporting Company as a Dividend

  11:35 AM | October 29, 2013

  Hemp (PublicWire.com Press Release) — LAS VEGAS, Oct. 29, 2013 /PRNewswire/ — Hemp, Inc., (OTC PINK: HEMP) on October 25, 2013 solidified its all-stock deal with BioAdaptives, Inc. by selling the assets of its subsidiary, BioSwan, Inc. According to Hemp, Inc., the deal distributes 2,000,000 shares of BioAdaptives common stock to Hemp, Inc. shareholders. The distribution to Hemp shareholders will be based on percentage of ownership of common stock held and not applicable to preferred stock ownership. This distribution is

  Read more